An evidence-based medicine approach to optimising medication therapy in a patient with <i>Clostridium difficile</i> infection

  • N L Hoffmann University of the Western Cape
  • R Coetzee University of the Western Cape
Keywords: evidence-based medicine, optimising medication therapy, Clostridium difficile infection

Abstract

Adverse drug reactions (ADRs) are one of the most common causes of morbidity and mortality and approximately 70% of ADRs can be prevented. In Europe, 6.5% of hospitalisations are due to ADRs, quite similar to the estimated prevalence in South Africa (6.3%).1,2

Globally a rise in antimicrobial resistance is evident. Approximately 9.7% of multidrug-resistant tuberculosis (TB) patients have extensively drug-resistant TB (XDR-TB). Approximately 65% of Escherichia coli isolates are resistant to ciprofloxacin. Patients with methicillin-resistant Staphylococcus aureus (MRSA) have a 64% higher risk of mortality compared to patients with methicillin-sensitive Staphylococcus aureus.3,4

Author Biographies

N L Hoffmann, University of the Western Cape

School of Pharmacy, University of the Western Cape, South Africa

R Coetzee, University of the Western Cape

School of Pharmacy, University of the Western Cape, South Africa

Published
2019-12-02
Section
Forum